Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.06.14 | Graitres 2014 Sold Out, Orders Open for New Customers in 2016 | 217 | PR Newswire | DUBAI, UAE and PARIS, June 14, 2014 /PRNewswire/ --
Graitres is pleased to announce that its 2014 collection has sold out. On trend with the company's success, production orders for both the Graitres... ► Artikel lesen | |
14.06.14 | New Movie "America" Features Hillary Clinton First Meeting With Saul Alinsky | 153 | PR Newswire | LOS ANGELES, June 14, 2014 /PRNewswire/ --America, the new film from bestselling author Dinesh D'Souza and the Academy Award-winning producer of Schindler's List, Gerald R. Molen which hits theaters... ► Artikel lesen | |
14.06.14 | United Church of Christ Central Atlantic Conference Passes Resolution Calling for Washington Football Team Name Change and Calls for Member Boycott | 145 | PR Newswire | NEWARK, Del., June 14, 2014 /PRNewswire/ --The Central Atlantic Conference of the United Church of Christ passed a resolution at its annual meeting Saturday, June 14, pressuring the National Football... ► Artikel lesen | |
14.06.14 | Access Bank Supports the Broader Community as its UK SubsidiaryExperiences Continued Success in its Business | 156 | PR Newswire | LONDON, June 14, 2014 /PRNewswire/ --
Access Bank Group supports UNICEF through the high-profile Access Bank Charity Shield polo matches in Nigeria that have run for the past five years in conjunction... ► Artikel lesen | |
14.06.14 | Lexicon Presents LX4211 Data at American Diabetes Association Meeting | 23 | PR Newswire | THE WOODLANDS, Texas, June 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), presented data at the 74th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco... ► Artikel lesen | |
14.06.14 | Sanofi's Lyxumia (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering than Liraglutide when Both were Added to Insulin Glargine | 40 | PR Newswire | PARIS, June 14, 2014 /PRNewswire/ --Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia® (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus... ► Artikel lesen | |
14.06.14 | Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) | 84 | PR Newswire | PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300... ► Artikel lesen | |
14.06.14 | Patients Continuing On Sanofi's Lantus Had Lower Blood Sugar Levels Than Those who Switched to Insulin Detemir | 60 | PR Newswire | BRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ -- Sanofi US announced today results from a real world outcome study of type 2 diabetes (T2D) patients that show switching from Lantus® (insulin glargine... ► Artikel lesen | |
14.06.14 | Cities for Life Increased Community Support and Showed Improved Clinical Measures for People Living With or At Risk for Type 2 Diabetes | 132 | PR Newswire | SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- The American Academy of Family Physicians Foundation announced today that the Cities for Life program, supported by Sanofi US, helped decrease blood glucose... ► Artikel lesen | |
14.06.14 | NMR-based Diabetes Risk Index (DRI) Helps to Identify Normal-weight Individuals at High Risk of Progressing to Type 2 Diabetes | 26 | PR Newswire | SAN FRANCISCO, June 14, 2014 /PRNewswire/ --LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the... ► Artikel lesen | |
14.06.14 | Zosano Pharma, Inc. to Present at the 74th American Diabetes Association (ADA) Scientific Session | 22 | PR Newswire | FREMONT, Calif., June 14, 2014 /PRNewswire/ --Zosano Pharma, Inc., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, announced that... ► Artikel lesen | |
14.06.14 | Lilly's Once-Weekly Dulaglutide Shows Similar Reductions in Average Blood Glucose Levels as Once-Daily Liraglutide in Head-to-Head Trial | 23 | PR Newswire | SAN FRANCISCO, June 14, 2014 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) today released detailed results from dulaglutide's sixth AWARD trial, showing that once-weekly dulaglutide 1.5 mg was... ► Artikel lesen | |
14.06.14 | Lilly's Basal Insulin Peglispro Shows Novel Mechanism of Action | 44 | PR Newswire | SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data regarding the mechanism of action of basal insulin peglispro (BIL). When BIL and insulin glargine... ► Artikel lesen | |
14.06.14 | Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus | 51 | PR Newswire | SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance's... ► Artikel lesen | |
14.06.14 | New Phase 3 Study Shows Efficacy and Safety of Victoza (Liraglutide [rDNA origin] Injection) for the Treatment of Type 2 Diabetes in Adults with Moderate Renal Impairment | 58 | PR Newswire | SAN FRANCISCO, June 14, 2014 /PRNewswire/ --
Data from a new phase 3 study demonstrated that once-daily Victoza® (liraglutide [rDNA origin] injection) provided greater glycaemic control versus placebo... ► Artikel lesen | |
14.06.14 | Hundreds Join Moms Demand Action for Gun Sense in America Today for 2nd Annual Brooklyn Bridge March and Rally to End Gun Violence | 67 | PR Newswire | NEW YORK, June 14, 2014 /PRNewswire-USNewswire/ -- A crowd of more than800gathered in Brooklyn this morning for the "2nd Annual Brooklyn Bridge March and Rally to End Gun Violence." The event, hosted... ► Artikel lesen | |
14.06.14 | New One-year Data of IDegLira Shows Glucose-lowering Effect was Maintained for People With Type 2 Diabetes | 38 | PR Newswire | SAN FRANCISCO, June 14, 2014 /PRNewswire/ --
New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment... ► Artikel lesen | |
14.06.14 | Phase 3a Data Showed Liraglutide 3 mg Demonstrated Significantly Greater Weight Loss Compared to Placebo in Adults With Obesity and Type 2 Diabetes | 40 | PR Newswire | SAN FRANCISCO, June 14, 2014 /PRNewswire/ --
Today, primary results from SCALE' Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1)... ► Artikel lesen | |
14.06.14 | Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In The Bancorp Inc. (TBBK) To Contact The Firm | 30 | PR Newswire | NEW YORK, June 14, 2014 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at The Bancorp Inc. ("Bancorp" or the "Company") (NASDAQ:... ► Artikel lesen | |
14.06.14 | Lifshitz & Miller Law Firm Announces Investigation of Annie's, Inc., Montage Technology Group Limited, OpenTable, Inc., Provectus Biopharmaceuticals, Inc., and The Bancorp Inc. | 48 | PR Newswire | NEW YORK, June 14, 2014 /PRNewswire/ -- Annie's, Inc. Lifshitz & Miller announces that a class action was filed in the United States District Court for the Northern District of California alleging... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
EVOTEC | 806 |
BAYER | 470 |
NEL | 405 |
BYD | 393 |
TUI | 358 |
DEUTSCHE BANK | 338 |
NVIDIA | 308 |
RWE | 304 |
TESLA | 283 |
SUPER MICRO COMPUTER | 282 |
MERCEDES-BENZ | 279 |
RHEINMETALL | 265 |
PLUG POWER | 257 |
AIXTRON SE | 218 |
RENK GROUP | 211 |
DEUTSCHE LUFTHANSA | 205 |
VOLKSWAGEN | 202 |
APPLE | 193 |
BIONTECH | 192 |
PALANTIR TECHNOLOGIES | 192 |
ALLIANZ | 178 |
AMAZON | 178 |
COMMERZBANK | 168 |
SIEMENS ENERGY | 166 |
NORDEX | 162 |